Johnston, J B <br/><br/>
P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.  [electronic resource] 

 -  Leukemia & lymphoma  Aug 1997 
 - 435-49 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.3109/10428199709050881  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--pharmacology<br/>Chlorambucil--pharmacology<br/>Drug Resistance, Neoplasm<br/>Drug Screening Assays, Antitumor<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Nuclear Proteins<br/>Polymorphism, Single-Stranded Conformational<br/>Prognosis<br/>Proto-Oncogene Proteins--metabolism<br/>Proto-Oncogene Proteins c-bcl-2--metabolism<br/>Proto-Oncogene Proteins c-mdm2<br/>RNA, Messenger--metabolism<br/>Tumor Cells, Cultured<br/>Tumor Suppressor Protein p53--metabolism<br/>Vidarabine--analogs & derivatives<br/>bcl-2-Associated X Protein